Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials

Proceedings of the Society for Experimental Biology and Medicine

Volumn 216, Issue 2, 1997, Pages 151-165

  Boone, Charles W ^a   Bacus, James W ^b   Bacus, James V ^b   Steele, Vernon E ^a   Kelloff, Gary J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Olympus America Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIESTROGEN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BETA CAROTENE; CARBENOXOLONE; CAROTENOID; EFLORNITHINE; FINASTERIDE; FOLIC ACID; IBUPROFEN; LIMONENE; OLTIPRAZ; PIROXICAM; RETINOID; RETINOL; STEROID 5ALPHA REDUCTASE INHIBITOR; SULINDAC;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; CARCINOMA IN SITU; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHROMOSOME BREAKAGE; DIET SUPPLEMENTATION; GENE MUTATION; GENETIC STABILITY; HUMAN; REVIEW;

EID: 0030854311     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-216-44165     Document Type: Review

References (74)

1. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Sigman CC. Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85-89, 1994.
2. Wright N, Alison M. The Biology of Epithelial Cell Populations, 2 Vol. Oxford: Clarenden Press, 1984.
3. Coleman WB, Tsongalis GJ. Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem 41:644-657, 1995.
4. Wright N, Alison M. Cell proliferation during carcinogenesis in squamous epithelium. In: The Biology of Epithelial Cell Populations, 2 Vol. Oxford: Clarenden Press, Vol 1:pp421-444, 1984.
5. Amati B, Land H. Myc-Max-Mad: A transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 4:102-108, 1994.
6. Levine AJ, Broach JR. Oncogenes and cell proliferation. Curr Opin Genet Dev 5:1-4, 1995.
7. Crissman JD, Zarbo RJ. Dysplasia, in situ carcinoma, and progression to invasive squamous cell carcinoma of the upper aerodigestive tract. Am J Surg Pathol 13(Suppl 1):5-16, 1989.
8. Lymboussaki A, Kaipainen A, Hatva E, Vastrik I, Jeskanes L, Jalkanen M, Werner S, Stenback F, Alitalo R. Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin. Br J Cancer 73:1347-1355, 1996.
9. Bonner MP, Culin C, Reed JC, Further E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146:20-26, 1995.
10. Jacobsen MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci 21:83-86, 1996.
11. Willis RA. Pathology of Tumors (2nd ed). London: Butterworths, pp 23, 1953.
12. Kerr JFR, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 107:41-44, 1972.
13. Foulds L. Neoplastic Development. New York: Academic Press, Vol 1:pp92, 1969.
14. Anderson MC. Premalignant and malignant diseases of the cervix. In: Fox H, Ed. Haines and Taylor Obstetrics and Gynecological Pathology. New York: Churchill Livingston, pp225-277, 1987.
15. Irwin CR, Schor SL, Ferguson MWJ. Expression of EGF-receptors on epithelial and stromal cells of normal and inflamed gingiva. J Periodontal 26:388-394, 1991.
16. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis: A critical review. N Engl J Med 316:1654-1658, 1987.
17. Ferguson AR. Associated bilharziosis and primary malignant disease of the urinary bladder, with observations on a series of forty cases. J Pathol Bacteriol 16:76-94, 1911.
18. Kantor AF, Hartge P, Hoover RN, Fraumeni JF. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res 48:3853-3855, 1988.
19. Locke JR, Hill DE, Walzer Y. Incidence of squamous cell carcinoma in patients with long-term catheter drainage. J Urol 133:1034-1035, 1985.
20. Yamagiwa H. Mucosal dysplasia of gallbladder: Isolated and adjacent lesions to carcinoma. Jpn J Cancer Res 80:238-243, 1989.
21. Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, Reid BJ. Barrett's esophagus: A model of human neoplastic progression. Cold Spring Harb Symp Quant Biol 59:577-583, 1994.
22. Fielding JWL, Allum WH. Premalignancy and Early Cancer in General Surgery. New York: Oxford University Press, pp167, 1996.
23. Blackwell KE, Fu Y, Calcaterra TC. Laryngeal dysplasia. Cancer 75:457-463, 1995.
24. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 52:1651-1659, 1992.
25. Butterworth BE, Popp JA, Connolly RB, Goldsworthy TL. Chemically-induced cell proliferation in carcinogenesis. In: Vaino H, Magee PN, McGregor DB, McMichael AJ, Eds. Mechanisms of Carcinogenesis in Risk Identification. IARC Scientific Publ. No. 116. Lyon, France: IARC Publications, pp279-305, 1992.
26. Cohen SM, Ellwein LB. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51:6493-6505, 1991.
27. Cohen SM, Wellwein LB. Pivotal role of increased cell proliferation in . carcinogenesis. Mod pathol 4:371-382, 1991.
28. Farber E. Cell proliferation as a major risk factor for cancer: A concept of doubtful validity. Cancer Res 55:3759-3762, 1995.
29. Stemmermann GN, Noffsinger A, Fenoglio-Preiser CM, p4267; Ames BN, Gold LS, pp4267-4268; Cohen SM, Ellwein LB, pp4269-4270; Butterworth BE, pp4270-4271; with response by Dr. Farber, pp4272-4274. Correspondence in Letters to the Editor. Cancer Res 56:4267-4274, 1995.
30. Cheng KC, Loeb LA. Genomic instability and tumor progression: Mechanistic considerations. Adv Cancer Res 60:121-156, 1993.
31. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10:934-947, 1996.
32. Stark GR. Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 61:87-113, 1993.
33. Wahl G. The importance of circular DNA in mammalian gene amplification. Cancer Res 49:1333-1340, 1989.
34. Hahn PJ. Molecular biology of double-minute chromosomes. Bioessays 15:477-184, 1993.
35. Eiserich JP, van der Vliet A, Handelman GJ, Halliwell B, Cross CE. Dietary antioxidants and cigarette smoke-induced biomolecular damage: A complex interaction. Am J Clin Nutr 62(Supp]):1490S-1500S, 1995.
36. Mirvish SS. Experimental evidence for inhibition of N-nitroso compound formation as a factor in the negative correlation between vitamin C consumption and the incidence of certain cancers. Cancer Res 54(Suppl 7):1948S-1951S, 1994.
37. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 6:963-968, 1951.
38. Nelson MA, Einspahr JG, Alberts DS, Balfour CA, Wymer JA, Welch KL, Salaxche SJ, Bangert JL, Grogan TM, Bozzo PO. Analysis of p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 85:23-29, 1994.
39. Bito T, Ueda M, Ahmed NU, Nagano T, Ichihashi M. Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinom in relation to p53 expression. J Cutan Pathol 22:427-434, 1995.
40. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532, 1988.
41. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence hybridization. Cancer Res 55:5408-5414, 1995.
42. Nowell PC. The clonal evolution of tumor cell populations. Science 194:23-28, 1976.
43. Nowell PC. Mechanisms of tumor progression. Cancer Res 46:2203-2207, 1986.
44. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 52:1651-1659, 1992.
45. Ames B, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Aci USA 92:5258-5265, 1995.
46. Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 249:970-971, 1990.
47. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146:3-15, 1995.
48. Richart RM. A radioautographic analysis of cellular proliferation in dysplasia and carcinoma in situ of the uterine cervix. Am J Obstet Gynecol 86:925-930, 1963.
49. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488-2492, 1996.
50. Voravud N, Shin DM, Ro JY, Lee JS, Hong WK, Hittelman WN. Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 53:2874-2883, 1993.
51. MacAulay C, Lam S, Payne PW, LeRiche JC, Palcic B. Malignancy-associated changes in bronchial epithelial cells in biopsy specimens. Anal Quant Cytol Histol 17:55-61, 1995.
52. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nature Med 1:902-909, 1995.
53. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, Donis-Keller H. Allelotyping of ductal carcinoma in situ of the breast: Deletion of loci on 8p, 13q, 16q, 17p, and 17q. Cancer Res 55:3399-3405, 1995.
54. Fujii H, Szumel R, March C, Zhou W, Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56:5260-5265, 1996.
55. Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, Zoumpourlis V, Rowley H, Taylor K, Whittaker J, Howard P, Beirne JC, Gosney JR, Woolgar J, Vaughan ED, Spandidos DA, Jones AS. Allelotype of squamous cell carcinoma of the head and neck: Fractional allelic loss correlates with survival. Br J Cancer 72:1180-1188, 1995.
56. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 54:531-538, 1994.
57. Ittmann M. Allelic loss on chromasome 10 in prostate adenocarcinoma. Cancer Res 56:2143-2147, 1996.
58. Schnipper LE. Clinical implications of tumor cell heterogeneity. N Engl J Med 314:1423-1431, 1994.
59. Kelloff GJ, Boone CW, Eds. Cancer chemopreventive agents: Drug development status and future prospects I. J Cell Biochem Suppl 20: 1-304, 1994.
60. Kelloff GJ, Boone CW, Eds. Cancer chemopreventive agents: Drug development status and future prospects II. J Cell Biochem Suppl 22:1-262, 1995.
61. Kelloff GJ, Boone CW, Eds. Cancer chemopreventive agents: Drug development status and future prospects III. J Cell Biochem Suppl 26:1-322, 1996.
62. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidranmsky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271:659-662, 1996.
63. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91:9871-9875, 1994.
64. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelsetin B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102-105, 1992.
65. Palcic B, Lam S, Hung J, MacAulay C. Detection and localization of early lung cancer by imaging techniques. Chest 99:742-743, 1991.
66. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW, Kelloff GJ. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI Drug Development Program. J Cell Biochem Suppl 20:32-54, 1994.
67. Marnett LJ. Aspirin and related nosteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 24:103-106, 1995.
68. Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNA repair, and cell division: Three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 101(Suppl 5):35-44, 1993.
69. Boone CW, Kelloff CJ, Freedman LS. Intraepithelial and postinvasive neoplasia as a stochastic continuum of clonal evolution, and its relationship to mechanisms of chemopreventive drug action. J Cell Biochem 17G:14-25, 1993.
70. Hoult JR, Moroney MA, Paya M. Actions of flavonoids and coumarins on lipoxygenase and cyclooxygenase. Methods Enzymol 234:443-454, 1994.
71. Pasricha PJ, Bedi A, O'Conner K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR, Giardiello FM. The effects of sulincac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109:994-998, 1995.
72. Hag JD, Gould MN. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34:477-483, 1994.
73. Boone CW, Kelloff GJ. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: Relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. J Cell Biochem Suppl 19:10-22, 1994.
74. Boone CW, Kelloff GJ. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. J Cell Biochem Suppl 17F:37-48, 1993.